openPR Logo
Press release

Acute Intermittent Porphyria Market 2018 – Kay Vendors are Dahaner (U.S.), F. Hoffmann-La Roche Ltd (Switzerland) and others.

02-26-2018 10:25 AM CET | Health & Medicine

Press release from: Market Research Future

Market Research Future

Market Research Future

Acute Intermittent Porphyria Market is expected to grow at a CAGR of 5.6 % during the forecast period 2017-2023. Although the prevalence of this disease is considered rare. Porphyria is a disorder that occurs when there is a build-up of the chemicals in the body that produce a substance called porphyrin. Acute intermittent porphyria (AIP) is a genetic metabolic disorder is one of the 8 types of porphyria. It affects the production of heme, the oxygen-binding prosthetic group of hemoglobin. Children have a 50% chance of inheriting any of the 8 different types of porphyria if their parents have the disorder.

Increasing prevalence of rare diseases, rising demand for better treatment, increasing investment in biotechnology and pharmaceutical industries for R&D, and availability of funds drive the growth of the market. Moreover, increasing government support for research & development, changing lifestyle, and rapidly developing technology is expected to fuel the market growth during the forecast period. However, high cost of the treatment may slow the market growth during the period 2017-2023.

Access Sample Copy @ https://www.marketresearchfuture.com/sample_request/4713 .

Regional Analysis:

The Americas dominate the global acute intermittent porphyria market owing to the presence of huge patient population with gastrointestinal problems, neurological issues, high healthcare spending, and increasing government support for research & development. 

Europe holds the second largest share of the global acute intermittent porphyria market as result of increasing focus of various government agencies on the treatment of rare diseases such as Acute Intermittent Porphyria. Moreover, the growing public awareness about Acute Intermittent Porphyria likely to boost the Europe market.

Asia Pacific is the fastest growing acute intermittent porphyria market across the globe. Japan holds the major share of the regional market due to availability of advanced technology and huge healthcare spending. Moreover, rapidly developing economy, increasing healthcare expenditure, and the government’s initiatives for research & development projected to drive the market in China and India over the forecasted period.

Get Discount on Acute Intermittent Porphyria Market Report @ https://www.marketresearchfuture.com/check-discount/4713 .

Key Players:

Some of key the players in the market are Dahaner (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Bio-Rad Laboratories, Inc.  (U.S.), Siemens AG (U.S.), ARKRAY, Inc. (Japan), Sysmex Corporation (Japan), and ACON Laboratories, Inc. (U.S.).

LIST OF TABLES:

Table 1 Acute Intermittent Porphyria Industry Synopsis, 2017-2023

Table 2 Global Acute Intermittent Porphyria Market Estimates And Forecast, 2017-2023, (USD Million)

Table 3 Global Acute Intermittent Porphyria Market By Region, 2017-2023, (USD Million)

Table 4 Global Acute Intermittent Porphyria Market By Diagnosis, 2017-2023, (USD Million)

Table 5 Global Acute Intermittent Porphyria Market By Treatment, 2017-2023, (USD Million)

Table 6 Global Acute Intermittent Porphyria Market By End Users, 2017-2023, (USD Million)

Table 7 North America Acute Intermittent Porphyria Market By Diagnosis, 2017-2023, (USD Million)

Table 8 North America Acute Intermittent Porphyria Market By Treatment, 2017-2023, (USD Million)

Table 9 North America Acute Intermittent Porphyria Market By End Users, 2017-2023, (USD Million)

Table 10 U.S. Acute Intermittent Porphyria Market By Diagnosis, 2017-2023, (USD Million)

Table 11 US Acute Intermittent Porphyria Market By Treatment, 2017-2023, (USD Million)

Table 12 US Acute Intermittent Porphyria Market By End Users, 2017-2023, (USD Million)

Table 13 Canada Acute Intermittent Porphyria Market By Diagnosis, 2017-2023, (USD Million)

Table 14 Canada Acute Intermittent Porphyria Market By Treatment, 2017-2023, (USD Million)

Table 15 Canada Acute Intermittent Porphyria Market By End Users, 2017-2023, (USD Million) and more.

Browse Complete Premium 125 Pages Half-Cooked Research Report Enabled with Respective Tables and Figures is Available @ https://www.marketresearchfuture.com/reports/acute-intermittent-porphyria-market-4713

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

+1 646 845 9312

Email: sales@marketresearchfuture.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Acute Intermittent Porphyria Market 2018 – Kay Vendors are Dahaner (U.S.), F. Hoffmann-La Roche Ltd (Switzerland) and others. here

News-ID: 957216 • Views:

More Releases from Market Research Future

9-Decanoic Acid Methyl Ester Market Poised for Strong 6.59% CAGR Growth Through 2035
9-Decanoic Acid Methyl Ester Market Poised for Strong 6.59% CAGR Growth Through …
The 9-decanoic acid methyl ester market is a growing sector driven by the increasing demand for bio-based and sustainable chemical products across various industries. With its unique properties, it finds application in flavors and fragrances, pharmaceuticals, personal care, and as a chemical intermediate. The market is projected to expand significantly in the coming years. Market Overview and Size The global 9-decanoic acid methyl ester market was valued at USD 230.0 million in
Washable Marker Market Poised for 3.54% CAGR Growth During 2024-2032
Washable Marker Market Poised for 3.54% CAGR Growth During 2024-2032
The washable marker market is a dynamic and growing segment within the broader stationery and art supplies industry. Driven by a blend of consumer demands for safety, convenience, and sustainability, the market is experiencing consistent expansion, particularly within the education and home-use sectors. While faced with some challenges, the industry's future looks promising, propelled by product innovation and evolving consumer trends. Get Sample @ https://www.marketresearchfuture.com/sample_request/41217 Market Size and Growth The global washable
Phone Car Mounts Market to Reach USD 7.37 Billion by 2034, Growing at 6.47% CAGR
Phone Car Mounts Market to Reach USD 7.37 Billion by 2034, Growing at 6.47% CAGR
The phone car mounts market, a critical sub-segment of the broader automotive accessories industry, is experiencing robust growth driven by a convergence of technological advancements, evolving consumer behavior, and increasingly stringent road safety regulations. As smartphones become indispensable for navigation, communication, and in-car entertainment, the demand for secure and convenient hands-free solutions continues to escalate. The global phone car mounts market was valued at USD 3.93 billion in 2024 and
Intravenous (IV) Solution Market Set to Grow to USD 26.60 Billion at 7.70% CAGR by 2032
Intravenous (IV) Solution Market Set to Grow to USD 26.60 Billion at 7.70% CAGR …
Market Overview: The Intravenous (IV) Solution Market is estimated to be valued at USD 13.9 billion in 2023 and is projected to reach USD 26.60 billion by 2032, expanding at a compound annual growth rate (CAGR) of 7.70% from 2024 to 2031. The market growth is attributed to the rising prevalence of chronic diseases, growing hospitalization rates, and increasing surgical procedures that require IV fluid administration. Intravenous solutions are critical

All 5 Releases


More Releases for Porphyria

What's Driving the Acute Intermittent Porphyria Market 2025-2034: Impact Of Risi …
What Are the Projections for the Size and Growth Rate of the Acute Intermittent Porphyria Market? There has been a robust growth in the market size of acute intermittent porphyria in the past few years. The market that was valued at $4.37 billion in 2024, is projected to increase to $4.66 billion in 2025, marking a compound annual growth rate (CAGR) of 6.7%. Factors such as increasing healthcare spending, a surge
Acute Intermittent Porphyria Market Acute Intermittent Porphyria Treatments, Siz …
According to a new report published by CoherentMI The acute intermittent porphyria market is estimated to be valued at USD 1.43 Billion in 2024 and is expected to reach USD 2.17 Billion by 2031, growing at a compound annual growth rate (CAGR) of 6.1% from 2024 to 2031. The Global Acute Intermittent Porphyria Market has recently been analyzed and explored by CoherentMI in their latest market research report. The
Enhance Genetic Testing Module for Acute Intermittent Porphyria
The "Acute Intermittent Porphyria Market" is a dynamic and rapidly evolving sector, with significant advancements and growth anticipated by 2031. Comprehensive market research reveals a detailed analysis of market size, share, and trends, providing valuable insights into its expansion. This report delves into segmentation and definition, offering a clear understanding of market components and drivers. Employing SWOT and PESTEL analyses, the study evaluates the market's strengths, weaknesses, opportunities, and threats,
Porphyria Targeting Therapies Market, 2021-2030
Roots Analysis has announced the addition of “Porphyria Targeting Therapies Market, 2021-2030” report to its list of offerings. Porphyria is a rare disorder that is characterized by excessive accumulation of porphyrin, a compound that aids in the formation of heme (an essential part of hemoglobin that helps carry oxygen in blood). Any anomaly caused by genetic or acquired abnormalities in heme biosynthesis (produced majorly in bone marrow and liver) can
Porphyria Therapeutics- Pipeline Analysis 2018, Clinical Trials & Results | Alny …
Porphyria is a group of disorders including cutaneous porphyria and acute porphyria. Cutaneous porphyria affects the skin while acute porphyria affects the nervous system. Porphyria cutanea tarda is the most common type of porphyria prevalent in the U.S. Download the sample report at: https://www.pharmaproff.com/request-sample/1043 The common symptoms of porphyria are abdominal pain, chest pain, increased blood pressure, increased heart rate, muscle weakness, cramping, blisters, itching, swelling, constipation, vomiting, mental disorders,
Global Swedish Porphyria Industry Assesment report 2018-2025
Swedish porphyria is a rare autosomal dominant metabolic disorder affecting the production of heme resulting from a deficiency of the porphobilinogen deaminase. It is the most common of the acute porphyrias. In 2018, the global Swedish Porphyria market size was xx million US$ and is forecast to xx million US in 2025, growing at a CAGR of xx% from 2018. In this study, 2017 has been considered as the base year